title: Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: first case series.
abstract: OBJECTIVE
  To report our preliminary experience using ferumoxytol as intravenous iron therapy for treating iron deficiency anemia in 6 pediatric patients with underlying gastrointestinal disease.
  
  
  METHODS
  Between October 2010 and February 2011, 6 patients aged 6 months to 16 years who had malabsorption and/or ongoing gastrointestinal blood loss were given ferumoxytol infusions at a dose of 5.8-12 mg elemental iron/kg over 15-60 minutes, followed by 1 hour of observation to monitor for adverse effects.
  
  
  CONCLUSIONS
  Thirteen separate ferumoxytol administrations were given to 6 pediatric patients with various gastrointestinal diseases, including inflammatory bowel disease and short bowel syndrome, and/or chronic parenteral nutrition dependence. Twelve of 13 infusions were well tolerated at 5.8-12 mg elemental iron/kg/dose. No patient experienced adverse events that required clinical intervention. One patient developed mild pruritus that resolved spontaneously.
  
  
  CONCLUSIONS
  Ferumoxytol doses of up to 12 mg elemental iron/kg administered over 15-60 minutes seem to be well tolerated in pediatric patients. Larger prospective studies are needed to determine the incidence and severity of adverse effects associated with ferumoxytol, both during administration and immediately after. Long-term studies will be required to assess to risk for iron overload toxicity.
authors: Pediatric Blood Management Program, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
authors: Nabil
authors: N
authors: Hassan
authors: Jill
authors: J
authors: Cahill
authors: Surender
authors: S
authors: Rajasekaran
authors: Karen
authors: K
authors: Kovey
mesh_terms: D000293:Adolescent; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D052203:Ferrosoferric Oxide / Q000008:administration & dosage* / Q000009:adverse effects; D005767:Gastrointestinal Diseases / Q000378:metabolism*; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous
chemical_list: D006397:Hematinics; D052203:Ferrosoferric Oxide